卡培他滨,口服5-氟尿嘧啶前药,目前用于治疗转移性结直肠癌和乳腺癌。指纹,也称为皮纹学,其特征是指尖上的脊和沟的图案,用于政府机构和个人电子设备的识别。描述了两名接受卡培他滨治疗并与药物相关的指纹丢失的乳腺癌妇女。PubMed用于单独和组合搜索以下术语:缺席,Adermatoglyphia,乳房,癌症,卡培他滨,癌,结肠,结直肠,皮肤象形学,指纹,氟尿嘧啶,脚,手,损失,恶性肿瘤,鼻咽,肿瘤学,reaction,直肠,皮肤,综合征,肿瘤,还有xeloda.审查了确定的论文,并评估了适当的参考文献。本文回顾了20例卡培他滨诱导的肿瘤患者的外翻特征。大多数患者接受2000mg/m2或3500mg,在分开的剂量中,每一天。手足综合征,严重程度从1级到4级不等,总是在指纹丢失发生之前。在开始卡培他滨后,早在两周至3½年就发现了黑斑病。患者通常不知道他们的指纹丢失,直到他们经历了试图进入美国的延误,无法处理政府文件或获得驾驶执照,或者无法访问他们的电话,需要指纹识别扫描的电脑或健身房。指纹的丢失对某些人来说是可逆的;然而,几个病人没有恢复他们的皮肤象形文字,指纹的功能质量,或者停药后两者兼而有之。随着指纹识别不仅在扫描技术方面而且在全球利用方面的不断进步,卡培他滨诱导的无花期的重要性将继续增加。因此,接受卡培他滨的患者必须意识到这种潜在的不良皮肤后遗症。
Capecitabine, an oral 5-fluorouracil prodrug, is currently used in the treatment of metastatic colorectal carcinoma and breast cancer. Fingerprints, also referred to as dermatoglyphics and characterized by the pattern of ridges and furrows on the fingertips, are used for identification by government agencies and personal electronic devices. Two women with breast cancer who were treated with capecitabine and developed drug-associated loss of their fingerprints are described. PubMed was used to search the following terms separately and in combination: absence, adermatoglyphia, breast, cancer, capecitabine, carcinoma, colon, colorectal, dermatoglyphics,
fingerprint, fluorouracil, foot, hand, loss, malignancy, nasopharyngeal, oncology, reaction, rectal, skin, syndrome, tumor, and xeloda. The papers identified were reviewed and appropriate references were evaluated. The characteristics of capecitabine-induced adermatoglyphia in 20 oncology patients are reviewed. Most of the patients received either 2000 mg/m2 or 3500 mg, in divided doses, each day. Hand-foot syndrome, varying in severity from grade 1 to grade 4, always preceded the onset of
fingerprint loss. The discovery of adermatoglyphia occurred as early as two weeks to as late as 3½ years after starting capecitabine. Patients were often unaware of their
fingerprint loss until they experienced delays attempting to enter the United States, were unable to process government documents or obtain a driver\'s license, or could not obtain access to their telephone, computer or gym which required
fingerprint identification scanning. The loss of fingerprints was reversible for some of the individuals; however, several of the patients did not recover their dermatoglyphics, the functional quality of their fingerprints, or both after discontinuing the drug. The significance of capecitabine-induced adermatoglyphia will continue to increase as
fingerprint identification continues to advance not only in scanning technology but also in global utilization. Therefore, it is essential that patients receiving capecitabine are aware of this potential adverse cutaneous sequellae.